Global Hyperimmune Globulins Market Size is projected to reach USD 3.4 Billion by 2035 | CAGR of 5.95%
Category: HealthcareAccording to a research report published by Spherical Insights & Consulting, the Global Hyperimmune Globulins Market is expected to grow from USD 1.8 Billion in 2024 to USD 3.4 Billion by 2035, at a CAGR of 5.95% during the forecast period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On "The Global Hyperimmune Globulins Market Size, Share, and COVID-19 Impact Analysis, By Type (Hepatitis B Immunoglobulin, Rabies Immunoglobulin, Tetanus Immunoglobulin, and Others), By Route of Administration (Intravenous, Intramuscular, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. " Detailed Report Decription Her-https://www.sphericalinsights.com/reports/hyperimmune-globulins-market
The hyperimmune globulins market refers to the worldwide industry that focuses on producing and selling high-titer antibodies derived from vaccinated or convalescent human plasma, specifically used for treating or preventing diseases like rabies, tetanus, and hepatitis B. The market is primarily driven by an increasing global burden of infectious diseases like hepatitis B, rabies, and tetanus, where immediate passive immunity is crucial for prevention and cure. There is an increasing demand for hyperimmune globulin across industrial, commercial, and technology-driven applications, along with continuous innovation and investment across major end-use sectors. An increased prevalence of infectious diseases and reliance on plasma derived therapies are propelling the hyperimmune globulins market. Further, strategic collaboration and government support are promoting the market. On the contrary, limited accessibility and affordability of human plasma are responsible for hampering the hyperimmune globulins market.
The hepatitis B immunoglobulin segment dominated the market with a substantial share in 2024 and is projected to grow at a significant CAGR during the forecast period.
Based on the type, the hyperimmune globulins market is divided into hepatitis B immunoglobulin, rabies immunoglobulin, tetanus immunoglobulin, and others. Among these, the hepatitis B immunoglobulin segment dominated the market with a substantial share in 2024 and is projected to grow at a significant CAGR during the forecast period. Hepatitis B immunoglobulin is used for intramuscular administration to prevent the transmission of hepatitis B virus post-exposure and should be part of a regimen that includes the hepatitis B vaccine. An increased prevalence of hepatitis B infection as well as its role in prevention and post-exposure prophylaxis are propelling the segmental market growth.
The intravenous segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the route of administration, the hyperimmune globulins market is divided into intravenous, intramuscular, and others. Among these, the intravenous segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. An increasing adoption of IV therapies in advanced healthcare settings and the launch of liquid incorporated immunoglobulin are propelling the market. Hyperimmune IVIG is purified from human donors who were recently vaccinated or are in the convalescent period recovering from an infection, and is currently indicated for postexposure prophylaxis of infections.
Get more details on this report -
North America is expected to hold the majority share of the global hyperimmune globulins market during the forecast period.
North America is expected to hold the majority share of the global hyperimmune globulins market during the forecast period. The U.S. is leading the regional market owing to an increasing prevalence of infectious diseases, public awareness about preventive healthcare, and advancements in plasma fractionation technologies. North America has a robust market ecosystem due to the presence of well-established healthcare facilities, an increase in infectious disease prevalence and its awareness. Further, a strong industrial presence and well-established regulations are promoting the hyperimmune globulins market.
Get more details on this report -
Asia Pacific is anticipated to grow at the fastest pace in the global hyperimmune globulins market during the forecast period. China is the leading country in the Asia Pacific hyperimmune globulins market, driven by an increasing healthcare expenditure, large patient population, and upsurging need for immunoglobulin products. In the Asia Pacific hyperimmune globulins market, increasing investment in healthcare infrastructure and accessibility to advanced medical care are promoting the market. Further, rapid industrialization, expanding manufacturing bases, urbanization, and adoption of cost-efficient technologies are contributing to propel the hyperimmune globulins market.
Major vendors in the global hyperimmune globulins market are CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG, Hualan Bio, ADMA Biologics, Shanghai RAAS, and Sichuan Yuanda Shuyang, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In January 2025, Kamada Ltd., a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced that it was awarded a contract with an international organization for the supply of KAMRAB and VARIZIG in Latin America for 2025-2027.
- In July 2024, Grifols, one of the world’s leading producers of plasma-derived medicines, announced that the United States Food and Drug Administration (FDA) had approved an expanded label for XEMBIFY, the company’s 20% subcutaneous immunoglobulin (SCIg), to include treatment-naïve patients with primary humoral immunodeficiencies (PI).
- In January 2024, CSL Behring, a business unit of global biotechnology leader CSL, announced the availability of a 10g prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid).
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Hyperimmune Globulins market based on the below-mentioned segments:
Global Hyperimmune Globulins Market, By Type
- Hepatitis B Immunoglobulin
- Rabies Immunoglobulin
- Tetanus Immunoglobulin
- Others
Global Hyperimmune Globulins Market, By Route of Administration
- Intravenous
- Intramuscular
- Others
Global Hyperimmune Globulins Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?